• Air Traffic Control
  • Govt Finance Report
  • Pension Reform
  • Events
  • Reason facebook
  • Reason twitter
  • Reason youtube
Reason Foundation
  • About
    • About Us
    • Contact Us
    • Email Newsletters
    • Events
    • FAQs
    • Jobs & Internships
    • Savas Award
    • Shop
    • Staff
    • Trustees & Officers
  • Experts

      Browse Our Experts

      • Aaron Smith
        Director of Education Reform
      • Adrian Moore
        Vice President of Policy
      • Baruch Feigenbaum
        Senior Managing Director, Transportation Policy
      • Geoff Lawrence
        Research Director
      • Guy Bentley
        Director of Consumer Freedom
      • Leonard Gilroy
        Vice President of Government Reform
      • Robert Poole
        Director of Transportation Policy
      • Vittorio Nastasi
        Director of Criminal Justice Policy
      • View All Experts
  • Topics

      Browse Our Topics

      • Air Traffic Control
      • Annual Highway Report
      • Consumer Freedom
      • Criminal Justice Reform
      • Drug Policy
      • Education
      • Gov’t Financial Transparency
      • Pension Reform
      • Technology
      • Transportation
      • Urban Growth and Land Use
      • View All Topics
  • Publications
    • Latest
    • Government Financial Project
    • Annual Highway Report
    • Annual Pension Report
    • Annual Privatization Report
    • Aviation Newsletter
    • Backgrounders
    • Commentaries
    • Data Visualization
    • Education Newsletter
    • Email Newsletters
    • Pension Reform Newsletter
    • Policy Studies
    • Psychedelics Newsletter
    • Public Schools Without Boundaries
    • Testimony
    • Transportation Newsletter
    • Amicus Briefs
  • Reason.com
  • Donate
    • Donate Online
    • Donate Crypto
    • Ways To Give
    • Torchbearer Society
    • Planned Giving

Topics › Drug Policy

Drug Policy

  • Ibogaine
  • Industrial Hemp
  • Marijuana Regulations
  • Medical Marijuana
  • Opioid Crisis
  • Psychedelics

  • How the FDA can safely approve a promising but controversial mental health drug
    How the FDA can safely approve a promising but controversial mental health drug

    Commentary by Gregory Ferenstein and Geoffrey Lawrence

  • A Schedule III designation is still overly restrictive for marijuana
    A Schedule III designation is still overly restrictive for marijuana

    Testimony by Geoffrey Lawrence and Jacob James Rich

  • States can legalize MDMA for pharmaceutical use even if the federal government does not
    States can legalize MDMA for pharmaceutical use even if the federal government does not

    Commentary by Gregory Ferenstein

  • New Jersey Senate Bill 2283 would decriminalize psilocybin
    New Jersey Senate Bill 2283 would decriminalize psilocybin

    Testimony by Leonard Gilroy, Geoffrey Lawrence and Gregory Ferenstein

  • Psychedelics Policy Newsletter: Massachusetts ballot initiative would foster access, state legislature momentum stalls, and more
    Psychedelics Policy Newsletter: Massachusetts ballot initiative would foster access, state legislature momentum stalls, and more

    Psychedelics Policy Newsletter by Gregory Ferenstein

  • State psychedelics legalization and policy roundup — May 2024
    State psychedelics legalization and policy roundup — May 2024

    Commentary by Gregory Ferenstein

  • Alaska considers much needed reduction in marijuana taxes
    Alaska considers much needed reduction in marijuana taxes

    Commentary by Madison Carlino

  • The prospects and perils of rescheduling cannabis
    The prospects and perils of rescheduling cannabis

    Commentary by Michelle Minton

  • Marijuana rescheduling is good news, but California still needs to reduce state taxes and regulations
    Marijuana rescheduling is good news, but California still needs to reduce state taxes and regulations

    Commentary by Michelle Minton and Geoffrey Lawrence

More Drug Policy

  • First
  • Prev
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • ...
  • 55
  • Next

Follow

  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • RSS

Email Updates

Get weekly updates from Reason.

This field is for validation purposes and should be left unchanged.

More About Reason Foundation

  • About
  • Contact
  • Donate
  • Email Newsletters
  • Events
  • Jobs and Internships
  • Policy Research
  • Reason magazine
  • Shop

Contact

Reason Foundation
5737 Mesmer Ave.
Los Angeles, CA 90230
(310) 391-2245

1630 Connecticut Ave NW
Suite 600
Washington, DC 20009
(202) 986-0916

Privacy Policy
Accessibility

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

 
 
Copyright © 2025 Reason Foundation